D-0871-2023 Class III Terminated
FDA drug recall D-0871-2023 was initiated by Amring Pharmaceuticals Inc on Jun 12, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity. The recall status is terminated (terminated May 29, 2024). Affected quantity: 48,989 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 21, 2023
- Initiation Date
- Jun 12, 2023
- Termination Date
- May 29, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 48,989 bottles
Product description
Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Distribution pattern
Nationwide in the USA.
Code information
Lots: X220317A and X220318A, exp. date 09/25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0871-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026